Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN.

Breast Cancer Res Treat. 2007 Jan;101(1):113-21. Epub 2006 Nov 18.

PMID:
17115111
2.

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.

Fleeman N, Martin Saborido C, Payne K, Boland A, Dickson R, Dundar Y, Fernández Santander A, Howell S, Newman W, Oyee J, Walley T.

Health Technol Assess. 2011 Sep;15(33):1-102. doi: 10.3310/hta15330. Review.

3.

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.

Ahern TP, Hertz DL, Damkier P, Ejlertsen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP.

Am J Epidemiol. 2017 Jan 15;185(2):75-85. doi: 10.1093/aje/kww178. Epub 2016 Dec 17. Review.

4.

CYP2D6 and tamoxifen: DNA matters in breast cancer.

Hoskins JM, Carey LA, McLeod HL.

Nat Rev Cancer. 2009 Aug;9(8):576-86. doi: 10.1038/nrc2683. Review.

PMID:
19629072
5.

Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.

Cronin-Fenton DP, Lash TL.

Expert Rev Clin Pharmacol. 2011 May;4(3):363-77. doi: 10.1586/ecp.11.18. Review.

6.

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V.

J Natl Compr Canc Netw. 2009 Feb;7(2):203-13. Review.

PMID:
19200418
7.

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.

Singh MS, Francis PA, Michael M.

Breast. 2011 Apr;20(2):111-8. doi: 10.1016/j.breast.2010.11.003. Epub 2010 Dec 24. Review.

PMID:
21185724
8.

Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?

Zembutsu H, Sasa M, Kiyotani K, Mushiroda T, Nakamura Y.

Expert Rev Anticancer Ther. 2011 Feb;11(2):185-93. doi: 10.1586/era.10.228. Review.

PMID:
21342038
9.

Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.

Zembutsu H.

Pharmacogenomics. 2015;16(3):287-96. doi: 10.2217/pgs.14.171. Review.

PMID:
25712191
10.

CYP2D6 polymorphisms and the impact on tamoxifen therapy.

Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD.

J Pharm Sci. 2007 Sep;96(9):2224-31. Review.

PMID:
17518364
11.

CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.

Higgins MJ, Stearns V.

Curr Oncol Rep. 2010 Jan;12(1):7-15. doi: 10.1007/s11912-009-0076-5. Review.

PMID:
20425602
12.

Pharmacogenomics of tamoxifen therapy.

Brauch H, Mürdter TE, Eichelbaum M, Schwab M.

Clin Chem. 2009 Oct;55(10):1770-82. doi: 10.1373/clinchem.2008.121756. Epub 2009 Jul 2. Review.

13.

Tamoxifen and CYP2D6: a contradiction of data.

Hertz DL, McLeod HL, Irvin WJ Jr.

Oncologist. 2012;17(5):620-30. doi: 10.1634/theoncologist.2011-0418. Epub 2012 Apr 24. Review.

14.

Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.

Goetz MP, Kamal A, Ames MM.

Clin Pharmacol Ther. 2008 Jan;83(1):160-6. Epub 2007 Sep 19. Review.

15.

Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?

Stearns V, Rae JM.

Expert Rev Mol Med. 2008 Nov 20;10:e34. doi: 10.1017/S1462399408000896. Review.

16.

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.

Lum DW, Perel P, Hingorani AD, Holmes MV.

PLoS One. 2013 Oct 2;8(10):e76648. doi: 10.1371/journal.pone.0076648. eCollection 2013. Review.

17.

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.

Dezentjé VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H.

Clin Cancer Res. 2009 Jan 1;15(1):15-21. doi: 10.1158/1078-0432.CCR-08-2006. Review.

18.

Coprescription of tamoxifen and medications that inhibit CYP2D6.

Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP.

J Clin Oncol. 2010 Jun 1;28(16):2768-76. doi: 10.1200/JCO.2009.23.8931. Epub 2010 May 3. Review. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

19.

Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.

Briest S, Stearns V.

Clin Adv Hematol Oncol. 2009 Mar;7(3):185-92. Review.

PMID:
19398943
20.

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.

Zeng Z, Liu Y, Liu Z, You J, Chen Z, Wang J, Peng Q, Xie L, Li R, Li S, Qin X.

Cancer Chemother Pharmacol. 2013 Aug;72(2):287-303. doi: 10.1007/s00280-013-2195-9. Epub 2013 May 28. Review.

PMID:
23712329

Supplemental Content

Support Center